Novo Nordisk A/S
NONOF
$96.13
-$1.25-1.29%
Weiss Ratings | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Excellent | |||
Risk Index | Good | |||
Risk Grade | B- | |||
Reward Grade | A+ | |||
Rating Factors | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Excellent | |||
Efficiency Index | Excellent | |||
Solvency Index | Excellent | |||
Total Return Index | Good | |||
Volatility Index | Good | |||
Beta / Standard Deviation | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.54 | |||
Price History | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -5.76% | |||
30-Day Total Return | 2.07% | |||
60-Day Total Return | -4.16% | |||
90-Day Total Return | 22.51% | |||
Year to Date Total Return | 41.36% | |||
1-Year Total Return | 51.38% | |||
2-Year Total Return | 68.76% | |||
3-Year Total Return | 184.87% | |||
5-Year Total Return | 318.68% | |||
52-Week High % Change | -10.26% | |||
52-Week Low % Change | 54.88% | |||
Price | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $108.51 | |||
52-Week Low Price | $62.88 | |||
52-Week Low Price (Date) | Dec 08, 2022 | |||
52-Week High Price (Date) | Nov 24, 2023 | |||
Valuation | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | $429.82B | |||
Enterprise Value | 426.78B | |||
Price/Earnings (TTM) | 40.47 | |||
Earnings Per Share (TTM) | 2.41 | |||
Earnings Per Share Growth | 42.91% | |||
Price/Earnings To Growth | 0.94 | |||
Price/Sales (TTM) | 14.19 | |||
Price/Book (Q) | 33.05 | |||
Enterprise Value/Revenue (TTM) | 13.85 | |||
Price | $96.13 | |||
Enterprise Value/EBITDA (TTM) | 29.23 | |||
Enterprise Value/EBIT | 31.65 | |||
Market Cap Category | Mega Cap | |||
Dividends and Shares | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 4.489B | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | 42.45% | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 45 44 44 88 88 | |||
Address | -- | |||
Website | www.novonordisk.com | |||
Country | Denmark | |||
Year Founded | 1923 | |||
Profitability | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 43.76% | |||
Profit Margin | 35.19% | |||
Management Effectiveness | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 22.60% | |||
Return on Equity | 93.10% | |||
Income Statement | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | $30.81B | |||
Total Revenue (TTM) | $30.81B | |||
Revenue Per Share | $6.86 | |||
Gross Profit (TTM) | $25.93B | |||
EBITDA (TTM) | $14.60B | |||
EBIT (TTM) | $13.48B | |||
Net Income (TTM) | $10.84B | |||
Net Income Avl. to Common (TTM) | $10.84B | |||
Total Revenue Growth (Q YOY) | 38.99% | |||
Earnings Growth (Q YOY) | 68.26% | |||
EPS Diluted (TTM) | $2.41 | |||
EPS Diluted Growth (Q YOY) | 70.09% | |||
Balance Sheet | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | $6.75B | |||
Cash Per Share (Q) | $1.50 | |||
Total Current Assets (Q) | $20.17B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | $13.19B | |||
Current Ratio (Q) | 0.824 | |||
Book Value Per Share (Q) | $2.95 | |||
Total Assets (Q) | $42.57B | |||
Total Current Liabilities (Q) | $24.47B | |||
Total Debt (Q) | $3.76B | |||
Total Liabilities (Q) | $29.38B | |||
Total Common Equity (Q) | $13.19B | |||
Cash Flow | NONOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -$6.15B | |||
Cash from Financing (TTM) | -$8.76B | |||
Net Change in Cash (TTM) | $416.03M | |||
Levered Free Cash Flow (TTM) | $9.31B | |||
Cash from Operations (TTM) | $15.43B | |||